Opdivo® (nivolumab) – Expanded indication
December 20, 2017 – Bristol-Myers Squibb announced the FDA approval of Opdivo (nivolumab) for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.
Download PDF
